COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.

Morales-Ortega, Alejandro; García de Tena, Jaime; Frutos-Pérez, Begoña; Jaenes-Barrios, Beatriz; Farfán-Sedano, Ana Isabel; Canales-Albendea, Miguel Ángel; Bernal-Bello, David

Morales-Ortega, Alejandro; García de Tena, Jaime; Frutos-Pérez, Begoña; Jaenes-Barrios, Beatriz; Farfán-Sedano, Ana Isabel; Canales-Albendea, Miguel Ángel; Bernal-Bello, David.

Morales-Ortega A; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
García de Tena J; Department of Medicine, Universidad de Alcalá, Madrid, Spain.
Frutos-Pérez B; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Jaenes-Barrios B; Castilla La Nueva Primary Health Care Center, Madrid, Spain.
Farfán-Sedano AI; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Canales-Albendea MÁ; Department of Hematology, Hospital Universitario La Paz, Madrid, Spain.
Bernal-Bello D; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.

Cancer ; 127(11): 1937-1938, 2021 06 01.

Article in English | MEDLINE | ID: covidwho-1130474

Subject(s)

COVID-19; Hematologic Neoplasms; Hematologic Neoplasms/drug therapy; Humans; Protein Kinase Inhibitors/adverse effects; Risk Factors; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Cancer Year: 2021 Document Type: Article Affiliation country: Cncr.33432

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google